Clinical trials: Advanced Malignant Solid Tumor
Malignant Solid Tumor
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug…
- Trial name
- NCT01606748
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors
BY101298 is an innovative DNA-dependent protein kinases (DNA-PK) highly selective small molecule inhibitor. DNA-dependent protein kinases (DNA-PK plays a key role in the NHEJ repair pathway to repair DNA double-strand breaks…
- Trial name
- NCT06462716
- Testing
- BY101298 Capsules
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
Advanced EGFR Positive Solid Tumor
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to…
- Trial name
- NCT04412616
- Testing
- ZZ06
- Where
- 5 sites in United States, China
- Volunteers
- 60 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Solid Tumor
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
- Trial name
- NCT06239298
- Testing
- ZG005 Powder for Injection, Donafenib Tosilate Tablets
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Lymphoma, Malignant, Advanced Solid Neoplasms
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
The purpose of this study is to characterize the effect of food on the single-dose PK of TAK-659 in participants with advanced solid tumors and/or lymphomas.
- Trial name
- NCT03359733
- Testing
- TAK-659
- Where
- 3 sites in United States
- Sponsor
- Calithera Biosciences, Inc
Advanced Solid Tumor, Non Small Cell Lung Cancer
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
- Trial name
- SYNERGY-101 (NCT05098132)
- Testing
- STK-012, pembrolizumab KEYTRUDA®, pemetrexed
- Where
- 47 sites in United States, Georgia and 2 more
- Volunteers
- 364 people
- Sponsor
- Synthekine
Advanced Solid Tumor
A Phase I Trial of Simmitinib in Advanced Solid Tumors
This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer.
- Trial name
- NCT04058587
- Testing
- Simmitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor
A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors
This study is a first-in-human, multicenter, open label, uncontrolled, non-randomized, phase 1a/1b study, to evaluate the safety, tolerability, and preliminary antitumor activity of NB002 in subjects with advanced solid tumors.
- Trial name
- NCT05924906
- Testing
- NB002
- Volunteers
- 30 people
- Sponsor
- Suzhou Neologics Bioscience Co., Ltd.
Solid Tumor, Adult, Advanced Solid Tumor
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT04859777
- Testing
- MPT-0118, MPT-0118 + pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Monopteros Therapeutics Inc.
Advanced Solid Tumor
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult…
- Trial name
- NCT05021367
- Testing
- TQB3823 tablets
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
This is a phase Ib/II study to evaluate the safety, tolerability, PK profile and preliminary efficacy of fruquintinib monotherapy or plus sintilimab for advanced solid tumors.
- Trial name
- NCT03903705
- Testing
- Fruquintinib in Combination with Sintilimab
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Hutchmed
Advanced Solid Tumor
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.
- Trial name
- NCT02836600
- Testing
- LY3039478
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose…
- Trial name
- MINOTAUR (NCT05147350)
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 38 people
- Sponsor
- Debiopharm International SA
Solid Tumor, Advanced Solid Tumor
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
- Trial name
- NCT06952010
- Testing
- XB628, Zanzalintinib
- Where
- 11 sites in United States
- Volunteers
- 303 people
- Sponsor
- Exelixis
Solid Tumor
Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer
Primary Objective: Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax.
- Trial name
- NCT01336582
- Testing
- taxotere
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Advanced Solid Tumor
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.
- Trial name
- NCT06992713
- Testing
- H1710 for Injection
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine…
- Trial name
- NCT06169579
- Testing
- ND-003 tablets
- Where
- 21 sites in China
- Volunteers
- 96 people
- Sponsor
- Shenzhen NewDEL Biotech, Co., Ltd
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05156866
- Testing
- TORL-2-307-ADC
- Where
- 12 sites in United States, South Korea
- Volunteers
- 163 people
- Sponsor
- TORL Biotherapeutics, LLC
Advanced Solid Tumor, Lymphoma
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.
- Trial name
- NEON-1 (NCT04186637)
- Testing
- ALPN-202
- Where
- 10 sites in United States, Australia
- Volunteers
- 62 people
- Sponsor
- Alpine Immune Sciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.